ATARA BIOTHERAPEUTICS, INC. (ATRA) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $1.00K; Additional Paid in Capital, Common StockUSD $1.99B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-2.00K; Retained Earnings (Accumulated Deficit)USD $-2.03B.
- 2026-03-31: Common Stock, Value, IssuedUSD $1.00K; Additional Paid in Capital, Common StockUSD $1.99B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $0.00; Retained Earnings (Accumulated Deficit)USD $-2.03B.
- 2025-12-31: Common Stock, Value, IssuedUSD $1.00K; Additional Paid in Capital, Common StockUSD $1.98B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $1.00K; Retained Earnings (Accumulated Deficit)USD $-2.02B.
- 2025-09-30: Common Stock, Value, IssuedUSD $1.00K; Additional Paid in Capital, Common StockUSD $1.98B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $2.00K; Retained Earnings (Accumulated Deficit)USD $-2.02B.
ATARA BIOTHERAPEUTICS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Additional Paid in Capital USD | Common Stock, Value, Outstanding USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.00K | $1.99B | $-2.00K | $-2.03B | $-37.00M | 3 month · $394.00K | (m) | (m) |
| 2026-03-31 | $1.00K | $1.99B | $0.00 | $-2.03B | $-37.31M | 3 month · $749.00K | (m) | (m) |
| 2025-12-31 | $1.00K | $1.98B | $1.00K | $-2.02B | $-38.50M | 12 month · $9.75M | (m) | (m) |
| 2025-09-30 | $1.00K | $1.98B | $2.00K | $-2.02B | $-36.63M | 3 month · $1.23M | (m) | (m) |
| 2025-06-30 | $1.00K | $1.98B | $0.00 | $-2.01B | $-35.04M | 3 month · $2.80M | (m) | (m) |
| 2025-03-31 | $1.00K | $1.96B | $0.00 | $-2.02B | $-55.07M | 3 month · $4.21M | (m) | (m) |
| 2024-12-31 | $1.00K | $1.96B | $8.00K | $-2.05B | $-97.28M | 12 month · $27.00M | (m) | (m) |
| 2024-09-30 | $1.00K | $1.95B | $22.00K | $-2.04B | $-90.54M | 3 month · $6.42M | (m) | (m) |
| 2024-06-30 | $0.00 | $1.91B | $-14.00K | $-2.02B | $-110.87M | 3 month · $6.34M | (m) | (m) |
| 2024-03-31 | $12.00K | $1.90B | $-55.00K | $-2.00B | $-98.31M | 3 month · $8.40M | (m) | (m) |
| 2023-12-31 | $0.00 | $1.87B | $-204.00K | $-1.97B | $99.23M | 12 month · $45.39M | (m) | (m) |
| 2023-09-30 | $10.00K | $1.86B | $-571.00K | $-1.91B | $-50.84M | 3 month · $11.14M | (m) | (m) |
| 2023-06-30 | $10.00K | $1.85B | $-933.00K | $-1.84B | $7.45M | 3 month · $12.55M | (m) | (m) |
| 2023-03-31 | $10.00K | $1.83B | $-1.24M | $-1.77B | $64.96M | 3 month · $11.76M | (m) | (m) |
| 2022-12-31 | $10.00K | $1.82B | $-2.07M | $-1.69B | $126.64M | 12 month · $53.84M | (m) | (m) |
| 2022-09-30 | $9.00K | $1.81B | $-2.96M | $-1.62B | $187.11M | 3 month · $14.02M | (m) | (m) |
| 2022-06-30 | $9.00K | $1.79B | $-2.62M | $-1.53B | $257.48M | 3 month · $14.12M | (m) | (m) |
| 2022-03-31 | $9.00K | $1.78B | $-1.89M | $-1.55B | $224.32M | 3 month · $14.34M | (m) | (m) |
| 2021-12-31 | $9.00K | $1.74B | $-368.00K | $-1.46B | $279.61M | 12 month · $53.87M | (m) | (m) |
| 2021-09-30 | $9.00K | $1.68B | $24.00K | $-1.37B | $310.14M | 3 month · $13.76M | (m) | (m) |
| 2021-06-30 | $8.00K | $1.62B | $62.00K | $-1.29B | $331.54M | 3 month · $13.81M | (m) | (m) |
| 2021-03-31 | $8.00K | $1.60B | $161.00K | $-1.20B | $399.04M | 3 month · $12.27M | (m) | (m) |
| 2020-12-31 | $8.00K | $1.59B | $296.00K | $-1.12B | $462.34M | 12 month · $51.35M | (m) | (m) |
| 2020-09-30 | $8.00K | $1.40B | $527.00K | $-1.04B | $353.94M | 3 month · $13.26M | (m) | (m) |
| 2020-06-30 | $7.00K | $1.35B | $810.00K | $-968.93M | $381.12M | 3 month · $13.95M | (m) | (m) |
| 2020-03-31 | $6.00K | $1.14B | $204.00K | $-891.47M | $252.82M | 3 month · $12.64M | (m) | (m) |
| 2019-12-31 | $6.00K | $1.11B | $220.00K | $-817.96M | $290.78M | 12 month · $51.70M | (m) | (m) |
| 2019-09-30 | $5.00K | $1.06B | $233.00K | $-739.47M | $318.44M | 3 month · $12.15M | (m) | (m) |
| 2019-06-30 | $5.00K | $899.67M | $173.00K | $-667.57M | $232.28M | 3 month · $15.20M | (m) | (m) |
| 2019-03-31 | $5.00K | $877.13M | $38.00K | $-593.24M | $283.93M | 3 month · $12.27M | (m) | (m) |
| 2018-12-31 | $5.00K | $866.54M | $-340.00K | $-527.35M | $339.22M | 12 month · $33.82M | (m) | (m) |
| 2018-09-30 | $5.00K | $850.84M | $-449.00K | $-447.34M | $403.05M | 3 month · $9.25M | (m) | (m) |
| 2018-06-30 | $5.00K | $841.98M | $-505.00K | $-388.98M | $452.50M | 3 month · $8.00M | (m) | (m) |
| 2018-03-31 | $4.00K | $777.80M | $-524.00K | $-338.09M | $439.18M | 3 month · $7.01M | (m) | (m) |
| 2017-12-31 | $3.00K | $474.66M | $-151.00K | $-296.65M | $177.86M | 12 month · $23.10M | (m) | (m) |
| 2017-09-30 | $3.00K | $467.38M | $-88.00K | $-261.34M | $205.96M | (m) | (m) | (m) |
| 2017-06-30 | $3.00K | $451.50M | $-114.00K | $-230.24M | $221.14M | (m) | (m) | (m) |
| 2017-03-31 | $3.00K | $436.10M | $-152.00K | $-202.81M | $233.13M | (m) | (m) | (m) |
| 2016-12-31 | $3.00K | $431.07M | $-183.00K | $-177.16M | $253.74M | 12 month · $16.78M | (m) | (m) |
| 2016-09-30 | $3.00K | $429.09M | $35.00K | $-158.92M | $270.20M | (m) | (m) | (m) |
| 2016-06-30 | $3.00K | $423.60M | $193.00K | $-133.55M | $290.25M | (m) | (m) | (m) |
| 2016-03-31 | $3.00K | $418.45M | $51.00K | $-114.67M | $303.83M | (m) | (m) | (m) |
| 2015-12-31 | $3.00K | $413.73M | $-518.00K | $-98.11M | $315.10M | 12 month · $10.25M | (m) | (m) |
| 2015-09-30 | $3.00K | $410.56M | $51.00K | $-76.86M | $333.75M | (m) | (m) | (m) |
| 2015-06-30 | $2.00K | $214.31M | $-66.00K | $-64.99M | $149.25M | (m) | (m) | (m) |
| 2015-03-31 | $2.00K | $216.16M | $-18.00K | $-50.05M | $166.09M | (m) | (m) | (m) |
| 2014-12-31 | $2.00K | $144.17M | $-100.00K | $-40.89M | $103.18M | 12 month · $10.10M | (m) | (m) |
| 2014-10-31 | (m) | $74.60M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | $-11.00K | $-30.36M | $-23.03M | (m) | $7.34M | (m) |
| 2013-12-31 | $1.00K | $2.20M | (m) | $-12.88M | $-11.02M | 12 month · $1.71M | $2.20M | $2.20M |
| 2012-12-31 | (m) | (m) | (m) | (m) | $-3.73M | 4 month · $292.00K | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |